ConductScience.org, home

Paper34999727

Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.

Loschi M and 7 others. Bone Marrow Transplant, 2022. Cited by 52 papers, by iCite.

Cite this record

ConductScience Library. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Papers, record 34999727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34999727

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2022
PubMed
Publication types
Case Reports, Letter
PubMed
Citations, by iCite
52
iCite
Relative citation ratio, by iCite
3.56
iCite
Revised in PubMed
2026-10-10
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Loschi MMichaelhttps://orcid.org/0000-0002-4460-5939
2Roux CChristian
3Sudaka IIsabelle
4Ferrero-Vacher CCorinne
5Marceau-Renaut AAlice
6Duployez NNicolas
7Passeron TThierry
8Cluzeau TThomashttps://orcid.org/0000-0002-6745-1127

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematologic NeoplasmsMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Myelodysplastic SyndromesMajor topic
Humans
Mutation
Ubiquitin-Activating Enzymes

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132320566Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.N Engl J Med2020https://conductscience.org/library/papers/32320566PubMed
233619558Therapeutic options in VEXAS syndrome: insights from a retrospective series.Blood2021https://conductscience.org/library/papers/33619558PubMed
326922775Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.Leuk Res2016https://conductscience.org/library/papers/26922775PubMed
434427584Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.Blood Adv2021https://conductscience.org/library/papers/34427584PubMed
524507810Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?Best Pract Res Clin Haematol2013https://conductscience.org/library/papers/24507810PubMed
628088653Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.Leuk Res2017https://conductscience.org/library/papers/28088653PubMed
726875020Autoimmune diseases and myelodysplastic syndromes.Am J Hematol2016https://conductscience.org/library/papers/26875020PubMed
834714914Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience.Blood Adv2022https://conductscience.org/library/papers/34714914PubMed
934651299Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.Br J Haematol2022https://conductscience.org/library/papers/34651299PubMed
1033108101Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.N Engl J Med2020https://conductscience.org/library/papers/33108101PubMed
1134632574Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.Br J Dermatol2022https://conductscience.org/library/papers/34632574PubMed
1234046042Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome.Front Immunol2021https://conductscience.org/library/papers/34046042PubMed
1334611997VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis.Arthritis Rheumatol2022https://conductscience.org/library/papers/34611997PubMed
1434077653Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease.N Engl J Med2021https://conductscience.org/library/papers/34077653PubMed
1520850913[Systemic and autoimmune manifestations in myelodysplastic syndromes].Rev Med Interne2011https://conductscience.org/library/papers/20850913PubMed

Download CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.

PMIDTitleJournalYearIn PapersSource
42358941Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report.Front Immunol2026https://conductscience.org/library/papers/42358941PubMed
42221689Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report.Clin Hematol Int2026https://conductscience.org/library/papers/42221689PubMed
40977752JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.Dermatol Res Pract2025https://conductscience.org/library/papers/40977752PubMed
40869252VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/40869252PubMed
40846800Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.Clin Exp Med2025https://conductscience.org/library/papers/40846800PubMed
40195449Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.Nat Med2025https://conductscience.org/library/papers/40195449PubMed
39385260Rare primary vasculitis: update on multiple complex diseases and the new kids on the block.Adv Rheumatol2024https://conductscience.org/library/papers/39385260PubMed
39347920Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients.Clin Rheumatol2024https://conductscience.org/library/papers/39347920PubMed
39168911Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.Ann Hematol2024https://conductscience.org/library/papers/39168911PubMed
39081801Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.Hemasphere2024https://conductscience.org/library/papers/39081801PubMed
39060513Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.Bone Marrow Transplant2024https://conductscience.org/library/papers/39060513PubMed
38967099Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers.RMD Open2022https://conductscience.org/library/papers/38967099PubMed
38665946Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.Front Oncol2024https://conductscience.org/library/papers/38665946PubMed
38627861Unveiling the clinical spectrum of relapsing polychondritis: insights into its pathogenesis, novel monogenic causes, and therapeutic strategies.Adv Rheumatol2024https://conductscience.org/library/papers/38627861PubMed
38410307Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review.Cureus2024https://conductscience.org/library/papers/38410307PubMed
38330178Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.Blood Adv2024https://conductscience.org/library/papers/38330178PubMed
38130326VEXAS Syndrome-Diagnostic Clues for the Dermatologist and Gaps in Our Current Understanding: A Narrative Review.JID Innov2024https://conductscience.org/library/papers/38130326PubMed
38091008Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome.Blood Adv2023https://conductscience.org/library/papers/38091008PubMed
37738165Intrapatient competition of VEXAS syndrome and CML clones.Blood Adv2023https://conductscience.org/library/papers/37738165PubMed
37666646Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism.Ann Rheum Dis2023https://conductscience.org/library/papers/37666646PubMed

See all 28 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
UBA17317PubTator's text mininghttps://conductscience.org/library/genes/7317

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34999727

GET https://conductscience.org/api/papers/v1/34999727/cited_by?page=2